Nektar Therapeutics

NKTR hat gerade einen fetten sprung gemacht, waren die ganze zeit schon +4 % rum, jetzt auf einmal +10 prozent bei hohen umsätzen..aber noch keine meldung gefunden...
kommt wohl gleich...

da kam dann gestern doch noch was:

Here's Why Nektar Therapeutics Surged Today

Shares of Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company, are on the move following its presentation at the J.P. Morgan Healthcare conference. The stock climbed 11.1% during Tuesday's session as investors cheered Nektar's 2019 to-do list.

So what
Nektar has commercial-stage drugs, but sales and royalty revenue from partners that market its treatments trickled in at just $41 million during the first nine months of 2019. Investors nervous about NKTR-214 and its ability to boost the efficacy of PD-1 checkpoint inhibitors have hammered the stock more than 60% lower since a peak last March.

Last year, Bristol-Myers Squibb (NYSE: BMY) paid Nektar $1.85 billion up front for rights to NKTR-214. Investors were encouraged to hear that the company finished 2018 with $1.92 billion in cash and investments, thanks largely to Bristol's contribution.

In 2019, Nektar has a lot of plans for that cash, including:

Potential approval and launch of NKTR-181, an abuse-deterrent opioid painkiller that doesn't induce an addictive state of euphoria.
Human proof-of-concept data from a potential new autoimmune drug, NKTR-358.
Two new phase 1b studies of NKTR-358 in autoimmune conditions, to be initiated by Eli Lilly.
A phase 1 study of NKTR-255 in multiple myeloma.

...

https://finance.yahoo.com/news/apos-why-...00012.html

Why Nektar Therapeutics Stock Is Crashing Today

Shares of Nektar Therapeutics (NASDAQ: NKTR) were trading 34.5% lower as of 11:22 a.m. EDT on Friday. The plunge resulted from the biotech's second-quarter update after the market closed on Thursday.

Nektar's financial performance wasn't the issue. However, the company announced in its Q2 conference call that it had discovered manufacturing issues with two batches of experimental drug bempegaldesleukin used in early clinical studies. These issues also appeared to contribute to a delay in finalizing the development program for bempeg and Opdivo with Nektar's partner, Bristol-Myers Squibb (NYSE: BMY).


...

https://finance.yahoo.com/news/why-nekta...00007.html